Clinical Trials
8 trialsNCT02076646 2022-04-14
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Philogen S.p.A.
Phase 1/2 Unknown
NCT00615160 2021-10-06
PTK/ZK in Disseminated Malignant Melanoma
University Hospital Schleswig-Holstein
Phase 1/2 Terminated
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT01133977 2016-10-10
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Eisai Inc.
Phase 1/2 Completed
NCT00597038 2013-12-16
A Phase I/II Study of Dasatinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00246012 2013-08-19
A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
Centocor, Inc.
Phase 1/2 Completed
NCT00496223 2011-02-23
A Phase I/II Study of Sunitinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00327600 2010-09-15
Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
AmpliMed Corporation
Phase 1/2 Completed